Published in Cell Death Dis on July 03, 2014
IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis. PLoS One (2015) 0.92
CXCR7 stimulates MAPK signaling to regulate hepatocellular carcinoma progression. Cell Death Dis (2014) 0.82
Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus. Onco Targets Ther (2015) 0.82
CXCR7 expression in nasopharyngeal carcinoma tissues correlates with disease severity. Int J Clin Exp Med (2015) 0.78
Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model. J Exp Clin Cancer Res (2016) 0.78
Caloric restriction and the adipokine leptin alter the SDF-1 signaling axis in bone marrow and in bone marrow derived mesenchymal stem cells. Mol Cell Endocrinol (2015) 0.77
CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR. Oncotarget (2016) 0.76
Elevated expression of IFN-inducible CXCR3 ligands predicts poor prognosis in patients with non-metastatic clear-cell renal cell carcinoma. Oncotarget (2016) 0.75
Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cells. Front Pharmacol (2016) 0.75
Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System. Int J Endocrinol (2014) 0.75
CXCL12-induced macropinocytosis modulates two distinct pathways to activate mTORC1 in macrophages. J Leukoc Biol (2016) 0.75
Epithelial-to-mesenchymal transition in FHC-silenced cells: the role of CXCR4/CXCL12 axis. J Exp Clin Cancer Res (2017) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
mTOR signaling in growth control and disease. Cell (2012) 29.21
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc (2007) 12.39
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol (2004) 12.12
A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med (2006) 6.86
Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature (2003) 5.57
The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem (2005) 5.45
Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods (2000) 3.89
CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A (2007) 3.85
Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol (2009) 3.41
The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem (2007) 3.38
CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood (2009) 3.20
Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta (2009) 2.89
Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7. Proc Natl Acad Sci U S A (2009) 2.76
CXCR4 and CXCR7 have distinct functions in regulating interneuron migration. Neuron (2011) 2.69
CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia (2008) 2.66
Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol (2006) 2.50
CXCR7 functions as a scavenger for CXCL12 and CXCL11. PLoS One (2010) 2.28
Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells. J Exp Med (2008) 2.25
Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J Immunol (2009) 2.19
Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene (2006) 2.07
AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol (2009) 1.99
The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res (2010) 1.87
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood (2009) 1.86
CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. J Biol Chem (2011) 1.78
Cxcr7 controls neuronal migration by regulating chemokine responsiveness. Neuron (2011) 1.76
mTOR inhibitors in cancer therapy. Cancer Lett (2012) 1.59
Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J Exp Clin Cancer Res (2010) 1.59
Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol (2010) 1.55
Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br J Cancer (2011) 1.53
Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene (2012) 1.48
Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia (2011) 1.44
Small molecule inhibitors of CXCR4. Theranostics (2013) 1.30
Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas. Int J Cancer (2010) 1.28
Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol (2011) 1.27
Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer. Curr Cancer Drug Targets (2010) 1.25
Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells. Eur J Cancer (2008) 1.21
CXCR7 impact on CXCL12 biology and disease. Trends Mol Med (2012) 1.19
CXCR7 is an active component of SDF-1 signalling in astrocytes and Schwann cells. J Cell Sci (2010) 1.13
Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells. J Biol Chem (2012) 1.05
RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho. Oncogene (2001) 0.93
Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases. PLoS One (2013) 0.92
Flow cytometric analysis of cell division by dilution of CFSE and related dyes. Curr Protoc Cytom (2013) 0.89
An undigested gliadin peptide activates innate immunity and proliferative signaling in enterocytes: the role in celiac disease. Am J Clin Nutr (2013) 0.88
Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action. Cancer Metastasis Rev (2012) 0.87
Chemokines as therapeutic targets in renal cell carcinoma. Expert Rev Anticancer Ther (2008) 0.86
CXCR7 transcription in human non-small cell lung cancer and tumor-free lung tissues; possible regulation upon chemotherapy. Virchows Arch (2008) 0.84
Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer. Neoplasia (2012) 0.83
Strong expression of chemokine receptor CXCR4 by renal cell carcinoma correlates with advanced disease. J Oncol (2008) 0.82
Involvement of mTOR in CXCL12 mediated T cell signaling and migration. PLoS One (2011) 0.79
Antitumor activity of interferon-β1a in hormone refractory prostate cancer with neuroendocrine differentiation. J Endocrinol Invest (2017) 0.75